Vical cuts 47 workers after recent Allovectin failure
This article was originally published in Scrip
Executive Summary
Vical will lay off 47 employees, cutting its work force by 39%, to focus on infectious disease vaccine programs following the recent Phase III failure of the intratumoral cancer immunotherapy Allovectin (velimogene aliplasmid) for metastatic melanoma.